ThiccSalmon
2021-12-28
.
Why Novavax Stock Is Sinking Today<blockquote>为什么 Novavax 股票今天下跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696830364,"tweetId":"696830364","gmtCreate":1640658930235,"gmtModify":1640658930235,"author":{"id":4095045970376330,"idStr":"4095045970376330","authorId":4095045970376330,"authorIdStr":"4095045970376330","name":"ThiccSalmon","avatar":"https://static.tigerbbs.com/bce05fd04a55471c3b4af0f4eb176350","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>.</p></body></html>","htmlText":"<html><head></head><body><p>.</p></body></html>","text":".","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696830364","repostId":1187889461,"repostType":4,"repost":{"id":"1187889461","kind":"news","pubTimestamp":1640657510,"share":"https://www.laohu8.com/m/news/1187889461?lang=zh_CN&edition=full","pubTime":"2021-12-28 10:11","market":"us","language":"en","title":"Why Novavax Stock Is Sinking Today<blockquote>为什么 Novavax 股票今天下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1187889461","media":"Motley Fool","summary":"What happened\nShares of Novavax(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The com","content":"<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Shares of <b>Novavax</b>(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?</p><p><blockquote>股份<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）截至美国东部时间周一上午 11:47 下跌 9.6%。该公司没有宣布任何新的进展。那么大幅下跌的背后是什么呢？</blockquote></p><p> Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p><p><blockquote>其他疫苗股的跌幅也没有那么大。有些人甚至上升了一点。这排除了对奥密克戎变体的担忧下降是 Novavax 股价下跌的主要因素的可能性。</blockquote></p><p> Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p><p><blockquote>相反，投资者可能对 Novavax 计划申请其 COVID-19 疫苗 NVX-CoV2373 的美国紧急使用授权 (EUA) 越来越焦虑。一些投资者也可能担心 Novavax 向美国食品药品监督管理局 (FDA) 提交的文件的质量，即使它没有再次经历申请延迟。</blockquote></p><p> CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p><p><blockquote>首席执行官斯坦利·埃克接受雅虎采访!上周四的《财经直播》可能无助于安抚投资者。当被问及何时向 FDA 提交文件时，埃尔克回答说：“可能是下周，但我坚持认为我们将在今年年底前完成这项工作。”</blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p><p><blockquote>只要 NVX-CoV2373 在美国申请的再次延迟对 Novavax 来说就不会是灾难性的，只要该公司在新的一年里尽快完成提交。然而，管理层的公信力肯定会再次受到重大打击。</blockquote></p><p> But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p><p><blockquote>但目前猜测 Novavax 本周不会完成美国 EUA 申请还为时过早。担心公司FDA包装的质量也是没有用的。Novavax 最近赢得了 NVX-CoV2373 的欧盟授权。这表明疫苗制造商可以成功满足监管机构的制造质量障碍。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p><p><blockquote>投资者不喜欢等待，但这正是他们目前对 Novavax 必须做的事情。该公司现在随时都可以完成 EUA 备案。它还可以在等待监管决定的其他国家获得新的授权。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Sinking Today<blockquote>为什么 Novavax 股票今天下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Sinking Today<blockquote>为什么 Novavax 股票今天下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-28 10:11</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么事</blockquote></p><p> Shares of <b>Novavax</b>(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?</p><p><blockquote>股份<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）截至美国东部时间周一上午 11:47 下跌 9.6%。该公司没有宣布任何新的进展。那么大幅下跌的背后是什么呢？</blockquote></p><p> Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p><p><blockquote>其他疫苗股的跌幅也没有那么大。有些人甚至上升了一点。这排除了对奥密克戎变体的担忧下降是 Novavax 股价下跌的主要因素的可能性。</blockquote></p><p> Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p><p><blockquote>相反，投资者可能对 Novavax 计划申请其 COVID-19 疫苗 NVX-CoV2373 的美国紧急使用授权 (EUA) 越来越焦虑。一些投资者也可能担心 Novavax 向美国食品药品监督管理局 (FDA) 提交的文件的质量，即使它没有再次经历申请延迟。</blockquote></p><p> CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p><p><blockquote>首席执行官斯坦利·埃克接受雅虎采访!上周四的《财经直播》可能无助于安抚投资者。当被问及何时向 FDA 提交文件时，埃尔克回答说：“可能是下周，但我坚持认为我们将在今年年底前完成这项工作。”</blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p><p><blockquote>只要 NVX-CoV2373 在美国申请的再次延迟对 Novavax 来说就不会是灾难性的，只要该公司在新的一年里尽快完成提交。然而，管理层的公信力肯定会再次受到重大打击。</blockquote></p><p> But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p><p><blockquote>但目前猜测 Novavax 本周不会完成美国 EUA 申请还为时过早。担心公司FDA包装的质量也是没有用的。Novavax 最近赢得了 NVX-CoV2373 的欧盟授权。这表明疫苗制造商可以成功满足监管机构的制造质量障碍。</blockquote></p><p> Now what</p><p><blockquote>现在呢</blockquote></p><p> Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p><p><blockquote>投资者不喜欢等待，但这正是他们目前对 Novavax 必须做的事情。该公司现在随时都可以完成 EUA 备案。它还可以在等待监管决定的其他国家获得新的授权。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/27/why-novavax-stock-is-sinking-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/12/27/why-novavax-stock-is-sinking-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187889461","content_text":"What happened\nShares of Novavax(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.\nInstead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.\nCEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"\nSo what\nYet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.\nBut it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.\nNow what\nInvestors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3558,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696830364"}
精彩评论